AAV-directed persistent expression of a gene encoding anti-nicotine antibody for smoking cessation

Science Translational Medicine

Volumn 4, Issue 140, 2012, Pages

  Hicks, Martin J ^a   Rosenberg, Jonathan B ^a   De, Bishnu P ^a   Pagovich, Odelya E ^a   Young, Colin N ^b   Qiu, Jian Ping ^a   Kaminsky, Stephen M ^a   Hackett, Neil R ^a   Worgall, Stefan ^a   Janda, Kim D ^c   Davisson, Robin L ^a,b   Crystal, Ronald G ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b Department of Obstetrics Gynecology   (United States)

^c SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; NICOTINE; NICOTINE ANTIBODY; PARVOVIRUS VECTOR; UNCLASSIFIED DRUG;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY AFFINITY; ANTIBODY SPECIFICITY; ANTIBODY TITER; ARTERIAL PRESSURE; ARTICLE; BINDING AFFINITY; BRAIN LEVEL; CONTROLLED STUDY; DRUG BINDING; DRUG EFFICACY; EMBRYO; GENE TRANSFER; GENETIC CODE; HEART CONTRACTION; HEART RATE; HUMAN; HUMAN CELL; LOCOMOTION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SMOKING CESSATION; VIRAL GENE DELIVERY SYSTEM; ADENO ASSOCIATED VIRUS; ANIMAL; C57BL MOUSE; GENETICS; IMMUNOLOGY; METABOLISM; METHODOLOGY;

ANIMALS; ANTIBODIES, MONOCLONAL; DEPENDOVIRUS; MALE; MICE; MICE, INBRED C57BL; NICOTINE; SMOKING CESSATION;

EID: 84863186975     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3003611     Document Type: Article

References (46)

1. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, Morbidity and Mortality Weekly Report (Centers for Disease Control and Prevention, Atlanta, GA, 2010), pp. 1125-1162.
2. A. J. Alberg, M. V. Brock, J. M. Samet, Epidemiology of lung cancer: Looking to the future. J. Clin. Oncol. 23, 3175-3185 (2005).
3. L. Blanco-Cedres, M. L. Daviglus, D. B. Garside, K. Liu, A. Pirzada, J. Stamler, P. Greenland, Relation of cigarette smoking to 25-year mortality in middle-aged men with low baseline serum cholesterol: The Chicago Heart Association Detection Project in Industry. Am. J. Epidemiol. 155, 354-360 (2002).
4. M. N. Hylkema, P. J. Sterk, W. I. de Boer, D. S. Postma, Tobacco use in relation to COPD and asthma. Eur. Respir. J. 29, 438-445 (2007).
5. K. Sebelius, How Tobacco Smoke Causes Disease: The Biology and Behavioral Basis for Smoking-Attributable Disease: A Report of the Surgeon General (U.S. Department of Health and Human Services, Atlanta, GA, 2010).
6. National Cancer Institute, Smoking and Tobacco Control Monograph 9: Cigars: Health Effects and Trends (National Cancer Institute, Bethesda, MD, 2011).
7. D. F. Church, W. A. Pryor, Free-radical chemistry of cigarette smoke and its toxicological implications. Environ. Health Perspect. 64, 111-126 (1985).
8. W. A. Pryor, K. Stone, Oxidants in cigarette smoke. Radicals, hydrogen peroxide, peroxynitrate, and peroxynitrite. Ann. N. Y. Acad. Sci. 686, 12-27 (1993).
9. J. E. Rose, F. M. Behm, E. C. Westman, R. E. Coleman, Arterial nicotine kinetics during cigarette smoking and intravenous nicotine administration: Implications for addiction. Drug Alcohol Depend. 56, 99-107 (1999).
10. J. Le Houezec, Role of nicotine pharmacokinetics in nicotine addiction and nicotine replacement therapy: A review. Int. J. Tuberc. Lung Dis. 7, 811-819 (2003).
11. N. L. Benowitz, P. Jacob III, Daily intake of nicotine during cigarette smoking. Clin. Pharmacol. Ther. 35, 499-504 (1984).
12. A. Tammimäki, W. J. Horton, J. A. Stitzel, Recent advances in gene manipulation and nicotinic acetylcholine receptor biology. Biochem. Pharmacol. 82, 808-819 (2011).
13. U. Maskos, B. E. Molles, S. Pons, M. Besson, B. P. Guiard, J. P. Guilloux, A. Evrard, P. Cazala, A. Cormier, M. Mameli-Engvall, N. Dufour, I. Cloëz-Tayarani, A. P. Bemelmans, J. Mallet, A. M. Gardier, V. David, P. Faure, S. Granon, J. P. Changeux, Nicotine reinforcement and cognition restored by targeted expression of nicotinic receptors. Nature 436, 103-107 (2005).
14. N. L. Benowitz, Pharmacology of nicotine: Addiction, smoking-induced disease, and therapeutics. Annu. Rev. Pharmacol. Toxicol. 49, 57-71 (2009).
15. M. C. Fiore, Treating Tobacco Use and Dependence: 2008 Update (U.S. Department of Health and Human Services, Atlanta, GA, 2008), pp. 1-256.
16. M. I. Damaj, S. D. Grabus, H. A. Navarro, R. E. Vann, J. A. Warner, L. S. King, J. L. Wiley, B. E. Blough, R. J. Lukas, F. I. Carroll, Effects of hydroxymetabolites of bupropion on nicotine dependence behavior in mice. J. Pharmacol. Exp. Ther. 334, 1087-1095 (2010).
17. R. Polosa, N. L. Benowitz, Treatment of nicotine addiction: Present therapeutic options and pipeline developments. Trends Pharmacol. Sci. 32, 281-289 (2011).
18. L. F. Stead, R. Perera, C. Bullen, D. Mant, T. Lancaster, Nicotine replacement therapy for smoking cessation. Cochrane Database Syst. Rev. 1, CD000146 (2008).
19. S. Singh, Y. K. Loke, J. G. Spangler, C. D. Furberg, Risk of serious adverse cardiovascular events associated with varenicline: A systematic review and meta-analysis. CMAJ 183, 1359-1366 (2011).
20. M. G. LeSage, D. E. Keyler, P. R. Pentel, Current status of immunologic approaches to treating tobacco dependence: Vaccines and nicotine-specific antibodies. AAPS J. 8, E65-E75 (2006).
21. C. D. Fowler, M. A. Arends, P. J. Kenny, Subtypes of nicotinic acetylcholine receptors in nicotine reward, dependence, and withdrawal: Evidence from genetically modified mice. Behav. Pharmacol. 19, 461-484 (2008).
22. M. R. Carrera, J. A. Ashley, T. Z. Hoffman, S. Isomura, P. Wirsching, G. F. Koob, K. D. Janda, Investigations using immunization to attenuate the psychoactive effects of nicotine. Bioorg. Med. Chem. 12, 563-570 (2004).
23. S. Isomura, P. Wirsching, K. D. Janda, An immunotherapeutic program for the treatment of nicotine addiction: Hapten design and synthesis. J. Org. Chem. 66, 4115-4121 (2001).
24. Y. Hieda, D. E. Keyler, J. T. VanDeVoort, J. K. Kane, C. A. Ross, D. E. Raphael, R. S. Niedbalas, P. R. Pentel, Active immunization alters the plasma nicotine concentration in rats. J. Pharmacol. Exp. Ther. 283, 1076-1081 (1997).
25. B. P. De, A. Heguy, N. R. Hackett, B. Ferris, P. L. Leopold, J. Lee, L. Pierre, G. Gao, J. M. Wilson, R. G. Crystal, High levels of persistent expression of a1-antitrypsin mediated by the nonhuman primate serotype rh.10 adeno-associated virus despite preexisting immunity to common human adeno-associated viruses. Mol. Ther. 13, 67-76 (2006).
26. M. A. Russell, C. Feyerabend, Cigarette smoking: A dependence on high-nicotine boli. Drug Metab. Rev. 8, 29-57 (1978).
27. E. C. Siu, R. F. Tyndale, Characterization and comparison of nicotine and cotinine metabolism in vitro and in vivo in DBA/2 and C57BL/6 mice. Mol. Pharmacol. 71, 826-834 (2007).
28. A. Y. Moreno, K. D. Janda, Immunopharmacotherapy: Vaccination strategies as a treatment for drug abuse and dependence. Pharmacol. Biochem. Behav. 92, 199-205 (2009).
29. P. Maurer, G. T. Jennings, J. Willers, F. Rohner, Y. Lindman, K. Roubicek, W. A. Renner, P. Müller, M. F. Bachmann, A therapeutic vaccine for nicotine dependence: Preclinical efficacy, and phase I safety and immunogenicity. Eur. J. Immunol. 35, 2031-2040 (2005).
30. A. Y. Moreno, M. R. Azar, N. A. Warren, T. J. Dickerson, G. F. Koob, K. D. Janda, A critical evaluation of a nicotine vaccine within a self-administration behavioral model. Mol. Pharm. 7, 431-441 (2010).
31. D. K. Hatsukami, D. E. Jorenby, D. Gonzales, N. A. Rigotti, E. D. Glover, C. A. Oncken, D. P. Tashkin, V. I. Reus, R. C. Akhavain, R. E. Fahim, P. D. Kessler, M. Niknian, M. W. Kalnik, S. I. Rennard, Immunogenicity and smoking-cessation outcomes for a novel nicotine immunotherapeutic. Clin. Pharmacol. Ther. 89, 392-399 (2011).
32. P. Maurer, M. F. Bachmann, Vaccination against nicotine: An emerging therapy for tobacco dependence. Expert Opin. Investig. Drugs 16, 1775-1783 (2007).
33. A. Pollack, Antismoking vaccine fails in late trial, New York Times, 18 July 2011.
34. Y. Hieda, D. E. Keyler, S. Ennifar, A. Fattom, P. R. Pentel, Vaccination against nicotine during continued nicotine administration in rats: Immunogenicity of the vaccine and effects on nicotine distribution to brain. Int. J. Immunopharmacol. 22, 809-819 (2000).
35. M. Pravetoni, D. E. Keyler, M. D. Raleigh, A. C. Harris, M. G. Lesage, C. K. Mattson, S. Pettersson, P. R. Pentel, Vaccination against nicotine alters the distribution of nicotine delivered via cigarette smoke inhalation to rats. Biochem. Pharmacol. 81, 1164-1170 (2011).
36. D. Robertson, C. J. Tseng, M. Appalsamy, Smoking and mechanisms of cardiovascular control. Am. Heart J. 115, 258-263 (1988).
37. R. Fernández, C. Larraín, P. Zapata, Acute ventilatory and circulatory reactions evoked by nicotine: Are they excitatory or depressant? Respir. Physiol. Neurobiol. 133, 173-182 (2002).
38. R. A. Nadeau, T. N. James, Effects of nicotine on heart rate studied by direct perfusion of sinus code. Am. J. Physiol. 212, 911-916 (1967).
39. O. George, G. F. Koob, Individual differences in prefrontal cortex function and the transition from drug use to drug dependence. Neurosci. Biobehav. Rev. 35, 232-247 (2010).
40. J. Fang, J. J. Qian, S. Yi, T. C. Harding, G. H. Tu, M. VanRoey, K. Jooss, Stable antibody expression at therapeutic levels using the 2A peptide. Nat. Biotechnol. 23, 584-590 (2005).
41. Y. Mao, S. Kiss, J. L. Boyer, N. R. Hackett, J. Qiu, A. Carbone, J. G. Mezey, S. M. Kaminsky, D. J. D'Amico, R. G. Crystal, Persistent suppression of ocular neovascularization with intravitreal administration of AAVrh.10 coding for bevacizumab. Hum. Gene Ther. 22, 1525-1535 (2011).
42. H. Niwa, K. Yamamura, J. Miyazaki, Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene 108, 193-199 (1991).
43. X. Xiao, J. Li, R. J. Samulski, Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. J. Virol. 72, 2224-2232 (1998).
44. R. Müller, Determination of affinity and specificity of anti-hapten antibodies by competitive radioimmunoassay. Methods Enzymol. 92, 589-601 (1983).
45. G. M. Butz, R. L. Davisson, Long-term telemetric measurement of cardiovascular parameters in awake mice: A physiological genomics tool. Physiol. Genomics 5, 89-97 (2001).
46. E. H. Cerny, R. Lévy, J. Mauel, M. Mpandi, M. Mutter, C. Henzelin-Nkubana, L. Patiny, G. Tuchscherer, T. Cerny, Preclinical development of a vaccine 'against smoking'. Onkologie 25, 406-411 (2002).